Abstract
Amyloid deposition of WT human β2-microglobulin (WT-hβ2m) in the joints of long-term hemodialysis patients is the hallmark of dialysis-related amyloidosis. In vitro, WT-hβ2m does not form amyloid fibrils at physiological pH and temperature unless co-solvents or other reagents are added. Therefore, understanding how fibril formation is initiated and maintained in the joint space is important for elucidating WT-hβ2m aggregation and dialysis-related amyloidosis onset. Here, we investigated the roles of collagen I and the commonly administered anticoagulant, low-molecular-weight (LMW) heparin, in the initiation and subsequent aggregation phases of WT-hβ2m in physiologically relevant conditions. Using thioflavin T fluorescence to study the kinetics of amyloid formation, we analyzed how these two agents affect specific stages of WT-hβ2m assembly. Our results revealed that LMW-heparin strongly promotes WT-hβ2m fibrillogenesis during all stages of aggregation. However, collagen I affected WT-hβ2m amyloid formation in contrasting ways: decreasing the lag time of fibril formation in the presence of LMW-heparin and slowing the rate at higher concentrations. We found that in self-seeded reactions, interaction of collagen I with WT-hβ2m amyloid fibrils attenuates surface-mediated growth of WT-hβ2m fibrils, demonstrating a key role of secondary nucleation in WT-hβ2m amyloid formation. Interestingly, collagen I fibrils did not suppress surface-mediated assembly of WT-hβ2m monomers when cross-seeded with fibrils formed from the N-terminally truncated variant ΔN6-hβ2m. Together, these results provide detailed insights into how collagen I and LMW-heparin impact different stages in the aggregation of WT-hβ2m into amyloid, which lead to dramatic effects on the time course of assembly.
Keywords: amyloid, protein aggregation, protein misfolding, collagen, extracellular matrix, fibril, β2-microglobulin, dialysis-related amyloidosis (DRA), glycosaminoglycan, heparin, MHC I
Introduction
Dialysis-related amyloidosis (DRA)5 is a severe condition that leads to progressive bone and joint atrophy in the majority of long-term hemodialysis patients (1–5). This disorder results from the deposition of amyloid plaques formed predominantly of WT human β2-microglobulin (WT-hβ2m) in joints and cartilage tissue (3, 6–8). In its nonpathogenic role, WT-hβ2m constitutes the light chain of the major histocompatibility complex class I, which functions in presenting antigens to T-cells (9). After dissociation from the major histocompatibility complex class I complex, WT-hβ2m is normally degraded and excreted by the kidneys (10). In renal failure, the concentration of β2m in the plasma is increased up to >60 times compared with that of healthy individuals (3, 6–8). Aggregation of WT-hβ2m then leads to the formation of amyloid plaques that are deposited almost exclusively in skeletal tissues (11), which are rich in extracellular matrix (ECM) components, including collagens and the glycosaminoglycans (GAGs) heparan sulfate and hyaluronic acid (12–15). The mechanism of recruitment of WT-hβ2m specifically to skeletal tissues is not fully understood, but ECM components, such as low molecular weight (LMW)-heparin (a GAG mimic, relevant here because this is given to all patients undergoing renal replacement therapy), apolipoprotein E, and collagen, have been found to enhance WT-hβ2m aggregation in vitro (13, 16–18). Amyloid fibrils have also been found associated with collagen fibrils in ex vivo deposits from DRA patients (13), and monomers of both WT-hβ2m and its natural proteolytic product, ΔN6-hβ2m, which lacks the N-terminal six amino acids, have been shown to have weak (KD: 4.1 × 10−4 m and 4.9 × 10−6 m, respectively (15)) affinities for collagen I at the pathophysiologic pH of 6.4 (12). Despite this evidence of the importance of LMW-heparin and collagen in amyloid formation, the mechanism(s) by which interactions with the reagents affect aggregation of WT-hβ2m and ΔN6-hβ2m remain unclear.
Compared with the intransigence of WT-hβ2m to form amyloid fibrils at pH 6–7 (19, 20), ΔN6-hβ2m readily forms amyloid at these pH values in vitro (21, 22). ΔN6-hβ2m comprises ∼30% of the hβ2m present in DRA deposits (21, 23) and contains a nonnative trans-X-P32, a prerequisite for amyloid formation (22, 24) that is retained in the amyloid fibril structure itself (25). Weak interactions between the apical loops of ΔN6-hβ2m and WT-hβ2m have been shown to promote amyloid formation of the normally innocuous WT-hβ2m (26, 27), suggesting a potential role of ΔN6-hβ2m in initiating fibril assembly of the WT protein. How ΔN6-hβ2m, collagen, and LMW-heparin together influence amyloid formation of WT-hβ2m, however, has remained unclear.
Here we used detailed analysis of the kinetics of amyloid formation to determine the role of collagen I, LMW-heparin, and ΔN6-hβ2m and their mixtures on amyloid fibril formation of WT-hβ2m. The results reveal that LMW-heparin and collagen I influence multiple phases of WT-hβ2m amyloid formation, including initiation, elongation, and secondary nucleation processes. Additionally, we found that the effects of collagen I on amyloid formation depend on whether fibril growth of WT-hβ2m is self-seeded or cross-seeded by ΔN6-hβ2m fibrils. Overall, the results shed new light on the mechanisms by which biologically relevant factors influence WT-hβ2m amyloid assembly. More generally, they reveal how the local environment can have a dramatic effect in defining the rate and mechanisms of protein assembly into amyloid.
Results
LMW-heparin and collagen I have a synergistic effect in the initiation of amyloid formation of WT-hβ2m
The hallmark of DRA is formation of proteinaceous deposits comprised of WT-hβ2m and ΔN6-hβ2m in the ECM-rich joint spaces (3). Because native WT-hβ2m does not form amyloid at neutral pH or at the slightly acidified pH (pH 6.2) in affected joints (18) unless co-solvents or copper ions are added (13, 16–19, 28–32) (Fig. 1A), we investigated how collagen I that is found in the ECM and GAGs (represented by LMW-heparin) affect the kinetics of aggregation of WT-hβ2m. Previous studies have demonstrated a role of these components in hβ2m amyloid assembly (13, 15, 17, 18, 33), but the precise mechanism(s) by which they affect aggregation, and the possible synergy between these different components, remained unclear. Using the enhancement of thioflavin T (ThT) fluorescence as a probe of amyloid formation, measurement of the resulting fibril growth kinetics showed that LMW-heparin (0.1 mg/ml) induces fibril formation of WT-hβ2m (0.47 mg/ml) within ∼30 h, resulting in the formation of long, straight fibrils typical of amyloid (Fig. 1, A and B). By contrast, collagen I did not induce amyloid formation in the absence of LMW-heparin over the time scale measured here (Fig. 1, C and D) (note, however, that collagen can promote amyloid fibril formation over much longer time scales, as previously reported (13)). The addition of both components revealed that collagen I modulates the kinetics of LMW-heparin–driven WT-hβ2m fibril formation in a complex manner (Fig. 1, E and F). At low concentrations (0.03–0.12 mg/ml), collagen I accelerates LMW-heparin–induced aggregation of WT-hβ2m, decreasing the lag time relative to the effect of LMW-heparin alone (Fig. 1E, light green colors, compared with Fig. 1A, blue). However, the addition of higher concentrations of collagen I (≥0.47 mg/ml) in the presence of LMW-heparin retards fibril formation by increasing the lag time (Fig. 1E, dark green colors; see also Fig. S1A). Enhancement of WT-hβ2m amyloid formation by collagen I is consistent with previous results, which have shown that collagen I alone can induce aggregation of WT-hβ2m (13). WT-hβ2m has also been shown to bind to both collagen I and LMW-heparin (12, 14, 15, 18). At high concentrations of collagen I, we assume that competition between collagen I and LMW-heparin binding to each other (KD: 7.9 × 10−8 m) (34), and binding to WT-hβ2m may reduce the availability of these components to interact with WT-hβ2m slowing its aggregation. Sequestration of WT-hβ2m nuclei/aggregates on the surface of the collagen I fibrils, which would be favored at high concentrations of collagen I, could also disfavor amyloid formation (see below) and contribute to the complex dose-dependent behavior observed.
Figure 1.
A, amyloid fibril formation of WT-hβ2m (40 μm) in the absence (purple) or presence (blue) of 0. 1 mg/ml LMW-heparin. B, negative stain TEM at the end of the aggregation reaction (80 h) for WT-hβ2m in the presence of 0.1 mg/ml LMW-heparin. C, effect of collagen I on WT-hβ2m aggregation in the absence of LMW-heparin. Collagen I concentrations are indicated in the panel in mg/ml. D, negative stain TEM of the sample at 1 mg/ml collagen after 80 h of incubation. E, effect of collagen I on WT-hβ2m aggregation in the presence of 0.1 mg/ml LMW-heparin. For each condition, a single ThT fluorescence (Norm. ThT fluoresc.) trace representative of the mean aggregation kinetics taken over at least three replicate experiments with three samples in each is shown (see also Fig. S1). F, representative negative stain TEM of the end point of the aggregation process in the presence of 1 mg/ml collagen I and 0.1 mg/ml LMW-heparin. Scale bar in all TEM panels indicates 100 nm. Note the schematic drawings used to annotate the different reagents present in different experiments (WT-hβ2m (purple), LMW-heparin (gray), and collagen I fibrils (yellow/red bundle)). These symbols are used throughout the manuscript to denote the additives included in each experiment.
Role of the collagen sequence and conformation in LMW-heparin–induced aggregation of WT-hβ2m
Collagen I can adopt a hierarchy of structures within the ECM (Fig. 2A). The canonical collagenous sequence consists of Gly-Xaa-Yaa triplets, where Xaa and Yaa can be any amino acid but are most often Pro and hydroxyproline (Hyp/O), respectively. Single collagen polypeptide chains fold into polyproline type II helices. Three such chains then twist together to form a triple helix that is stabilized by a network of interchain hydrogen bonds between Gly and Xaa of a neighboring chain (35). The triple helices further self-assemble into higher order fibrils. To determine the effects of collagen sequence and conformation on the aggregation kinetics of WT-hβ2m, the kinetics of LMW-heparin–induced aggregation were monitored in the presence of two different collagen mimetic peptides (CMPs), as well as denatured full-length collagen I. The CMP, Ac-(Pro-Hyp-Gly)10-GY-NH2 (named POG10), forms a stable triple helix conformation without additional native sequence fragments (36). However, this peptide does not form intermolecular interactions required to proceed to collagen fibril formation. Removal of only one Gly from the middle POG repeat (named Gly−) disrupts the triple helix conformation (37, 38). By contrast with the complex effects of collagen I fibrils on the lag time of LMW-heparin–induced aggregation of WT-hβ2m (Fig. 1E), incubation of WT-hβ2m monomers (0.47 mg/ml) with up to 1 mg/ml POG10 or Gly− peptide, in the presence of 0.1 mg/ml LMW-heparin did not significantly affect the lag time of fibril formation relative to the lag time in the absence of peptide (Fig. 2, B, D, and E, and Fig. S1, A, B, and D). Full-length collagen I denatured into single chains also had no significant effect on the lag time of aggregation (Fig. 2, C and E, and Fig. S1C). Hence, adoption of a triple helical collagen structure with a native sequence is required for collagen I to modulate the rate of LMW-heparin–induced WT-hβ2m aggregation, highlighting the specificity between the different surfaces involved in amyloid assembly.
Figure 2.
The effect of CMPs and denatured collagen chains on LMW-heparin–induced WT-hβ2m fibril formation. A, schematic of collagen hierarchical conformations, from the primary amino acid sequence, single-chain polyproline type II helix, triple helix of three single chains, and higher order fibrils. B–D, LMW-heparin–induced aggregation kinetics of WT-hβ2m (40 μm) in the presence of POG10 peptide (which forms a stable collagen triple helix; B), collagen I in the single chain form (C), and Gly− peptide (which does not form a stable triple helix; D). The concentration of the peptides added is indicated by color in the inset. All traces were obtained with 0.1 mg/ml LMW-heparin. Negative stain TEM micrographs of the end points are shown as an inset for each condition. Scale bar, 100 nm. E, box plot of the lag time for the WT-hβ2m aggregation in the presence or absence of 1 mg/ml collagen I fibrils (data taken from Fig. 1E), denatured collagen, or CMPs. WT, WT-hβ2m alone (no collagen or CMPs added); FIBRIL, WT-hβ2m plus collagen I fibrils; POG, WT-hβ2m plus POG10 peptide; SC, WT-hβ2m plus single chain collagen I; GLY−, WT-hβ2m plus Gly− peptide. The data are representative of three replicate experiments, with three samples in each. Asterisk denotes p < 0.002. Norm. ThT fluoresc., normal ThT fluorescence.
Surface-mediated aggregation of WT-hβ2m is protected by collagen I
To determine whether a stable complex is formed between WT-hβ2m monomer and/or fibrils and collagen I, samples were taken at different times during aggregation in the presence or absence of 0.1 mg/ml LMW-heparin, added to collagen I (1.0 mg/ml), and pelleted 10 min later by centrifugation at 5000 × g (see “Experimental procedures”). At this low centrifugation speed, only collagen I fibrils sediment, whereas WT-hβ2m (monomers, oligomers, and fibrils) remain in the supernatant. Whether WT-hβ2m monomers/small oligomers and/or fibrils bind collagen I was then determined by monitoring the band intensity of WT-hβ2m that pelleted with collagen I on an SDS-PAGE gel. These experiments showed that WT-hβ2m co-precipitates with collagen I fibrils only after an incubation time of 35 h (Fig. 3, A–C) (approximately the t50 of aggregation in the presence of 0.1 mg/ml LMW-heparin (Fig. 1A)). A higher extent of co-precipitation was observed after 85 h, by which time WT-hβ2m amyloid formation has reached completion in the presence of LMW-heparin (Figs. 1A and 3, A and C). These results show that the fibrillar form of WT-hβ2m interacts with collagen I fibrils most tightly, whereas species formed in the lag time appear not to bind collagen I tightly, at least at the detection limit of these experiments. Consistent with these results, interactions between WT-hβ2m monomers and LMW-heparin or collagen I were found to be weak as assessed by 1H-15N heteronuclear single quantum coherence NMR spectra. This was assessed by 1 h co-incubation of 80 μm 15N-WT-hβ2m with 0.2 mg/ml LMW-heparin and/or 2 mg/ml collagen I and measurement of the chemical shifts of backbone resonances. No significant chemical shift perturbations (or linewidth) were observed in these experiments (Fig. S2), suggesting that these interactions are too weak to detect by these methods under the conditions employed.
Figure 3.
A, co-pelleting of WT-hβ2m aggregated for different times with collagen I fibrils with/without 0.1 mg/ml LMW-heparin. SDS-PAGE analysis of the whole sample (w) and the pellet after sedimentation of collagen I by low-speed centrifugation (P). Molecular mass markers with masses in kDa are shown alongside. B, negative stain TEM micrograph of WT-hβ2m incubated in the presence of 1.0 mg/ml collagen I and 0.1 mg/ml LMW-heparin for 15 h, showing the presence of collagen I fibrils but no WT-hβ2m amyloid. C, as in B, but image taken after incubation for 65 h. WT-hβ2m amyloid can be clearly seen in this image alongside collagen I fibrils. The scale bar in each micrograph is 500 nm.
Because WT-hβ2m fibrils and collagen I were shown to interact by the co-pelleting assay, we next analyzed the effect of collagen I on seeded growth of WT-hβ2m fibrils (using WT-hβ2m fibril seeds produced in the presence of LMW-heparin (see “Experimental procedures”)). As expected, the addition of WT-hβ2m seeds (5–30%, v/v) enhances the rate of formation of WT-hβ2m fibrils, dependent on the seed concentration (Fig. 4A). Note that under these quiescent conditions and without seeds, no fibrils form (22, 24, 26). Interestingly, a biphasic curve is generated in the presence of fibril seeds, with the first (relatively small) increase in ThT fluorescence intensity occurring in the first 2 h (Fig. 4, A and inset). This phase presumably monitors the elongation of fibril ends by WT-hβ2m monomers. The addition of 1 mg/ml collagen I does not affect this phase (Fig. 4B). By contrast, the second phase, with larger ThT amplitude (Fig. 4A), is significantly retarded by the addition of 1 mg/ml collagen I (Fig. 4B and Fig. S3). In the presence of low concentrations (5%, v/v) of seeds and under quiescent conditions, these fibril-mediated interactions are the dominant processes of fibril formation. Hence, in these conditions, the interaction of collagen I with WT-hβ2m fibrils, observed by co-precipitation (Fig. 3A), protects against fibril surface-mediated growth of WT-hβ2m amyloid by masking the fibril surface.
Figure 4.
The effect of collagen I fibrils on self-seeded and cross-seeded growth with WT-hβ2m monomers. A, aggregation kinetics of WT-hβ2m in the presence of preformed WT-hβ2m seeds (5–30%, v/v). The inset shows an expanded plot over the first ∼2 h. B, as in A, but in the presence of 1 mg/ml collagen I. C, aggregation kinetics of WT-hβ2m in the presence of preformed ΔN6-hβ2m seeds (5–30%, v/v). The inset shows an expanded plot over the first ∼2 h. D, as in C, but upon addition of 1 mg/ml of collagen I. Three replicate experiments, with three samples in each were measured. Here, a single trace representative of the mean aggregation kinetics is shown. See also Fig. S3 for statistics. Norm. ThT fluoresc., normal ThT fluorescence.
The specificity of collagen I for WT-hβ2m fibrils was next probed by monitoring the effect of collagen I on reactions in which preformed seeds of ΔN6-hβ2m were used to cross-seed amyloid formation of WT-hβ2m monomers (Fig. 4, C and D). WT-hβ2m and ΔΝ6-hβ2m are known to co-aggregate (13, 18, 23), forming fibrils of a different morphology in vitro than those formed by each protein alone (27). The results showed that the effect of collagen I on the seeded aggregation of WT-hβ2m is highly dependent on the identity of the seeds added. The addition of ΔΝ6-hβ2m seeds to WT-hβ2m monomers also results in biphasic fibril growth curves (Fig. 4C). However, the rate of the initial phase is slower under all conditions for the cross-seeded reactions compared with the self-seeded reactions (Fig. S3A). Most notably, the secondary process, which occurs after rapid fibril elongation, is much less affected by collagen I in the cross-seeded reactions than when self-seeded (Fig. 4, compare B and D; see also Fig. S3B). Thus, the interference of collagen I with surface-mediated growth of WT-hβ2m fibrils depends on the morphology of the hβ2m fibril seeds, which differ when self-seeded and cross-seeded by ΔΝ6-hβ2m (27).
LMW-heparin promotes assembly of WT-hβ2m fibrils in both self-seeded and cross-seeded reactions
Finally, the effect of LMW-heparin on fibril formation of WT-hβ2m was monitored in seeded reactions to determine whether the addition of this GAG can outcompete the effect of collagen I on aggregation. When mixed, LMW-heparin is able to rescue the inhibitory effect of collagen I on secondary processes whether the reaction is self- or cross-seeded (Fig. 5, A–D, and Fig. S3). Thus, collagen I and LMW-heparin have different effects on WT-hβ2m aggregation at multiple phases of fibrillation. Collagen I acts primarily on the secondary surface-mediated growth of self-seeded fibrils and depends on whether the reaction is self-seeded or cross-seeded (compare Fig. 4, A and B, with Fig. 5, A and B). By contrast, LMW-heparin can enhance growth at all stages of aggregation and is insensitive to the distinct amyloid conformations produced by self-seeding or cross-seeding with ΔN6-hβ2m.
Figure 5.
The effect of LMW-heparin on self-seeded and cross-seeded growth with WT-hβ2m monomers. A, aggregation kinetics of WT-hβ2m in the presence of preformed WT-hβ2m seeds (5–30%, v/v) and 0.1 mg/ml LMW-heparin. The inset shows an expansion of the first ∼2 h. B, as in A, but in the presence of 0.1 mg/ml LMW-heparin and 1 mg/ml collagen I. C, aggregation kinetics of WT-hβ2m in the presence of preformed ΔN6-hβ2m seeds (5–30%, v/v) in the presence of 0.1 mg/ml LMW-heparin. The inset shows an expansion of the first ∼2 h. D, as in C, but in the presence of 0.1 mg/ml LMW-heparin and 1 mg/ml collagen I. Three replicate experiments, with three samples in each were acquired. See also Fig. S3. Norm. ThT fluoresc., normal ThT fluorescence.
Discussion
A detailed study of the effects of the local environment on the course of protein aggregation is important for understanding how amyloid formation may be initiated and substantiated in vivo. Previous studies have shown the effects of chaperones (39–41), metal ions (19, 32, 42), membranes (43), trifluoroethanol or SDS co-solvents (28, 29, 44), GAGs (18, 30, 45, 46), and other natural compounds (13, 17, 47) on the formation of amyloid fibrils in vitro. For some of these compounds, detailed kinetic analysis has revealed the effect of each reagent on the different kinetic steps in aggregation, including primary nucleation, elongation from fibril ends, and secondary processes such as fibril fragmentation and secondary nucleation (39–41, 43, 48). Such studies can provide important information on the role of biologically relevant and other compounds on amyloid formation, including how the different factors may act synergistically to alter the course of aggregation in an in vitro setting (17, 30).
Here we have adopted this approach by examining the effects of two macromolecules that are present in conditions relevant to DRA, collagen I, and the GAG LMW-heparin. Because WT-hβ2m is not prone to amyloid formation in the absence of co-factors at pathophysiological pH and temperature, understanding how the molecular components of the local environment affect WT-hβ2m amyloid formation and impact the kinetics of fibril formation is important for developing an understanding of hβ2m amyloidogenesis in DRA. In addition, how the biological environment affects the ability of ΔN6-hβ2m, which makes up ∼30% of the hβ2m component in DRA plaques (21, 23), to stimulate aggregation of WT-hβ2m may also shed light on how the aggregation of WT-hβ2m may be initiated in vivo.
Understanding amyloid formation of WT-hβ2m in mechanistic detail in the context of the ECM in joints and cartilage is extremely challenging, given the multicomponent composition it presents. Here, we have started to investigate aggregation in this environment by determining how different components relevant to DRA (collagen I and LMW-heparin) impact the different kinetic stages of WT-hβ2m aggregation. The studies presented show that LMW-heparin, collagen I, and ΔN6-hβ2m have different effects on the course of WT-hβ2m aggregation, which compete for the different stages of aggregate formation. First, under all conditions, LMW-heparin is able to promote the self-assembly of WT-hβ2m, decreasing the lag time and increasing the rate of fibril formation by affecting secondary stages, whether self-seeded or cross-seeded by ΔN6-hβ2m. Previous studies have shown that LMW-heparin binds and stabilizes WT-hβ2m amyloid fibrils, whereas the nonsulfated GAG hyaluronic acid has no effect on fibril stability or the rate of fibril formation, suggesting that ionic interactions between the GAG and WT-hβ2m must be involved (17). Determining the origins of molecular recognition between different species (monomers, oligomers, and fibrils) of WT-hβ2m and ΔN6-β2m and GAGs will require further exploration, for example by varying the patterns of sulfation, the identity of the carbohydrate moieties that differ between GAGs, and the length of the GAG, which have been shown previously to affect amyloid-GAG recognition (46, 50). Analysis of the effects of heparan sulfate, the most abundant GAG in the joint ECM, would be particularly important for hβ2m, although previous studies have shown that heparan sulfate and LMW-heparin have similar effects on seeded elongation of fibril growth using WT-hβ2m (17).
By contrast with LMW-heparin, collagen I has a more complex role on WT-hβ2m assembly into amyloid, affecting the lag time of fibril formation and secondary growth phases in different ways, dependent on the concentration added, the presence of LMW-heparin, the structural organization of the collagen added, and whether fibril growth of WT-hβ2m is self-seeded or cross-seeded by ΔN6-hβ2m fibrils. A decrease in the lag time of WT-hβ2m assembly occurs upon addition of low concentrations of collagen I and LMW-heparin relative to the addition of LMW-heparin alone, suggestive of one route for the initiation of WT-hβ2m assembly at pathophysiological pH and temperature. However, at high concentrations of collagen I, the lag time is extended. Collagen I fibrils also interact strongly with WT-hβ2m amyloid fibrils, suppressing surface-mediated growth (Fig. 6, top row) by competing for interactions with the WT-hβ2m fibril surface. Notably, a different fibril morphology formed by cross-seeding WT-hβ2m with ΔN6-hβ2m fibrils does not show this marked suppression of fibril formation by collagen I (Fig. 6, bottom row). Whether self-seeded or cross-seeded with ΔN6 fibril seeds, LMW-heparin is able to outcompete the binding of collagen I to WT-hβ2m fibrils, releasing the potential of the amyloid fibril surface to enhance fibril formation via secondary nucleation processes. These results are consistent with previous studies that also showed enhanced aggregation of WT-hβ2m in the presence of LMW-heparin (18, 24). In addition to its role in suppressing amyloid formation, interactions between collagen I and WT-hβ2m fibrils may prevent the clearance of amyloid from the joint space, providing an explanation for the localization of DRA plaques to joint and cartilage tissues. Other factors not investigated here, such as the presence of chaperones and/or other proteins, oxidation, glycation, or other post-translational modifications of the hβ2m sequence, the presence of Cu2+ ions, and shear flow within the joint space, may also contribute to amyloid formation (17, 19, 31, 40, 51, 52). Overall, therefore, the results portray a marked complexity in amyloid formation in the ECM, in which a finely tuned balance of different components (in this case collagen I, LMW-heparin, and ΔN6-hβ2m) affect the progression of hβ2m aggregation and its sequestration in the joints to give a pattern of amyloid deposition that is the hallmark of DRA.
Figure 6.
Schematic of the effect of ECM components on seeded WT-hβ2m aggregation. Top row, WT-hβ2m forms amyloid through self-seeded fibril growth. A secondary phase, fibril surface-mediated growth is enhanced by LMW-heparin and a co-mixture of LMW-heparin and collagen I but is suppressed by collagen alone. Bottom row, cross-seeding WT-hβ2m monomer with ΔN6-hβ2m seeds forms fibrils with a different conformation(27). The fibril surface mediated growth of these fibrils is also enhanced by LMW-heparin and the LMW-heparin and collagen I co-mixture but is not affected by collagen I alone.
Experimental procedures
Protein preparation
WT-hβ2m and ΔN6-hβ2m were expressed and purified as described previously (22). For NMR experiments, 15N- and 13C-labeled WT-hβ2m and ΔN6 hβ2m were prepared as described in Ref. 53.
Collagen preparation
Collagen type I (354249) from rat tail was purchased from BD Biosciences. Collagen was diluted to 3 mg/ml in 0.1 m acetic acid. Before use, it was dialyzed into 50 mm MES, 120 mm NaCl at pH 6.2. For preparation of collagen I fibrils, the dialyzed collagen was incubated at 37 °C for 1 h. For preparation of collagen single chains, the dialyzed collagen was incubated for 30 min at 70 °C. CMPs POG10 and Gly− were purchased from LifeTein and Tufts University Core facility, respectively, and were directly diluted into 50 mm MES, 120 mm NaCl at pH 6.2 to the concentrations specified.
Formation of fibril seeds
Fibrils of WT-hβ2m were assembled in 50 mm MES buffer, 120 mm NaCl at pH 6.2 in the presence of 0.1 mg/ml LMW-heparin (Iduron) in a BMG Fluostar Optima plate reader at 37 °C at 600 rpm. The fibrils were sonicated for 1 min, distributed in aliquots, and frozen in liquid nitrogen. The size of the seeds was determined using negative stain transmission EM (TEM).
Kinetic measurement of aggregation
WT-hβ2m and ΔN6-hβ2m fibrils were assembled in 50 mm MES buffer, 120 mm NaCl at pH 6.2. Fibril growth was performed in a BMG Fluostar Optima plate reader at 37 °C at 600 rpm (or quiescently in the case of seeded reactions). A final concentration of 10 μm ThT (Sigma) and 40 μm β2m was used. When required, seeds (5–30%, v/v) were added. The fibril yield was measured by centrifuging 50 μl of the end points at 14,000 × g, where amyloid fibrils are found in the pellet and soluble material remains in the supernatant and can be quantified spectrophotometrically.
Determination of the lag time of fibril growth
The lag times of fibril growth under different conditions were determined by fitting a tangent to the curve at the midpoint of the elongation phase and extrapolating this time to the baseline signal in the lag phase. The intersection point of these two lines was considered the lag time.
Determination of the elongation rate and the half-time of kinetics in the presence of seeds
ThT fluorescence curves were normalized to the final time point where ∼100% of the protein was converted to fibrils. In cases where this was not the case, and therefore there was no plateau in the fluorescence curves (such as in Fig. 4, B and D), the ThT signal was normalized to the corresponding value in the presence of LMW-heparin (Fig. 5, B and D) where the fibril yield was 100%. The observed elongation rate was calculated by fitting straight lines to the ThT fluorescence curves in the first hour of the normalized aggregation kinetics divided by the concentration of seeds. The t50 is the time taken to reach 50% of the maximal ThT fluorescence.
Collagen co-precipitation
40 μm WT-hβ2m (in the presence/absence of 0.1 mg/ml LMW-heparin) was incubated at 37 °C at 600 rpm in a BMG Fluostar Optima plate reader. At different time points, 40-μl aliquots were taken and mixed with 1 mg/ml of collagen I fibrils and incubated for 10 min. The sample was centrifuged at 5000 × g for 10 min. Samples in the absence of LMW-heparin were used as a control. The pellet was washed once with the incubation buffer, and the centrifugation step was repeated. The pellet and the supernatant were then separately analyzed using 15% (w/v) polyacrylamide Tris-Tricine gels. The gels were stained with Coomassie Instant Blue (Expedeon).
NMR spectroscopy
Samples of 15N-labeled protein (40–80 μm) in 50 mm MES buffer containing 120 mm NaCl, pH 6.2, 90% (v/v) H2O, 10% (v/v) D2O were used for NMR experiments. 1H-15N heteronuclear single quantum coherence spectra were collected in a Varian INOVA NMR spectrometer performing at 600 MHz and were processed in NMRPipe and analyzed using programs available in CCPNMR analysis (49, 54).
EM
At the end of fibril assembly, 10 μl of sample were applied to carbon-coated EM grids. The grids were then carefully dried with filter paper before samples were negatively stained by the addition of 10 μl of 2% (w/v) uranyl acetate. Micrographs were recorded on a JEOL JEM-1400 electron microscope.
Author contributions
N. B.-C., T. K. K., C. L. H., J. B., and S. E. R. conceptualization; N. B.-C. data curation; N. B.-C., C. L. H., J. B., and S. E. R. supervision; N. B.-C., C. L. H., J. B., and S. E. R. funding acquisition; N. B.-C., T. K. K., C. L. H., J. B., and S. E. R. investigation; N. B.-C., T. K. K., C. L. H., J. B., and S. E. R. methodology; N. B.-C., T. K. K., C. L. H., J. B., and S. E. R. writing-original draft; N. B.-C., C. L. H., J. B., and S. E. R. project administration; N. B.-C., T. K. K., C. L. H., J. B., and S. E. R. writing-review and editing; T. K. K., C. L. H., J. B., and S. E. R. formal analysis; T. K. K., C. L. H., J. B., and S. E. R. validation; T. K. K., C. L. H., J. B., and S. E. R. visualization.
Supplementary Material
Acknowledgments
We thank members of our laboratories for helpful discussions and Nasir Khan for excellent technical support. The NMR instrumentation was funded by Wellcome Trust Grant 094232 and by the University of Leeds.
This work was supported funded in part by National Institutes of Health Grant GM 45302 (to J. B.). This work was also supported by Marie Curie Intra-European Fellowship (IEF) Grant 300324 (to N. B.-C.), Wellcome Trust Grants 204963, 094232, and 092896 (to T. K. K. and S. E. R.), Grant FP7/2007–2013 from European Research Council (ERC) under European Union's Seventh Framework Programme ERC Grant Agreement 322408 (to S. E. R.), and American Heart Association Postdoctoral Fellowship 17POST33410326 (to C. L. H.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This article contains Figs. S1–S3.
- DRA
- dialysis-related amyloidosis
- hβ2m
- human β2-microglobulin
- ECM
- extracellular matrix
- ThT
- thioflavin T
- GAG
- glycosaminoglycan
- LMW
- low molecular weight
- CMP
- collagen mimetic peptide
- TEM
- transmission electron microscopy
- Tricine
- N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
References
- 1. Dember L. M., and Jaber B. L. (2006) Dialysis-related amyloidosis: late finding or hidden epidemic? Semin. Dial. 19, 105–109 10.1111/j.1525-139X.2006.00134.x [DOI] [PubMed] [Google Scholar]
- 2. Dzido G., and Sprague S. M. (2003) Dialysis-related amyloidosis. Minerva Urol. Nefrol. 55, 121–129 [PubMed] [Google Scholar]
- 3. Gejyo F., Yamada T., Odani S., Nakagawa Y., Arakawa M., Kunitomo T., Kataoka H., Suzuki M., Hirasawa Y., and Shirahama T. (1985) A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem. Biophys. Res. Commun. 129, 701–706 10.1016/0006-291X(85)91948-5 [DOI] [PubMed] [Google Scholar]
- 4. Muñoz-Gómez J., Bergadá-Barado E., Gómez-Pérez R., Llopart-Buisán E., Subías-Sobrevía E., Rotés-Querol J., and Solé-Arqués M. (1985) Amyloid arthropathy in patients undergoing periodical haemodialysis for chronic renal failure: a new complication. Ann. Rheum. Dis. 44, 729–733 10.1136/ard.44.11.729 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Scarpioni R., Ricardi M., Albertazzi V., De Amicis S., Rastelli F., and Zerbini L. (2016) Dialysis-related amyloidosis: challenges and solutions. Int. J. Nephrol. Renovasc. Dis. 9, 319–328 10.2147/IJNRD.S84784 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Hadjipavlou A., Lander P., Begin L., Bercovitch D., Davidman M., and Jakab E. (1988) Skeletal amyloidosis due to β2-microglobulinemia in a patient on hemodialysis: a case report. J. Bone Joint Surg. Am. 70, 119–121 10.2106/00004623-198870010-00019 [DOI] [PubMed] [Google Scholar]
- 7. Bardin T., Kuntz D., Zingraff J., Voisin M.-C., Zelmar A., and Lansaman J. (1985) Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheumatism 28, 1052–1058 10.1002/art.1780280913 [DOI] [PubMed] [Google Scholar]
- 8. Gejyo F., Odani S., Yamada T., Honma N., Saito H., Suzuki Y., Nakagawa Y., Kobayashi H., Maruyama Y., and Hirasawa Y. (1986) β2-Microglobulin: A new form of amyloid protein associated with chronic hemodialysis. Kidney Int. 30, 385–390 10.1038/ki.1986.196 [DOI] [PubMed] [Google Scholar]
- 9. Wieczorek M., Abualrous E. T., Sticht J., Álvaro-Benito M., Stolzenberg S., Noé F., and Freund C. (2017) Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front. Immunol. 8, 292 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Floege J., and Ketteler M. (2001) β2-Microglobulin-derived amyloidosis: an update. Kidney Int. Suppl. 78, S164–S171 [DOI] [PubMed] [Google Scholar]
- 11. Inoue S., Kuroiwa M., Ohashi K., Hara M., and Kisilevsky R. (1997) Ultrastructural organization of hemodialysis-associated β2-microglobulin amyloid fibrils. Kidney Int. 52, 1543–1549 10.1038/ki.1997.484 [DOI] [PubMed] [Google Scholar]
- 12. Homma N., Gejyo F., Isemura M., and Arakawa M. (1989) Collagen-binding affinity of β2-microglobulin, a preprotein of hemodialysis-associated amyloidosis. Nephron 53, 37–40 10.1159/000185699 [DOI] [PubMed] [Google Scholar]
- 13. Relini A., Canale C., De Stefano S., Rolandi R., Giorgetti S., Stoppini M., Rossi A., Fogolari F., Corazza A., Esposito G., Gliozzi A., and Bellotti V. (2006) Collagen plays an active role in the aggregation of β2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J. Biol. Chem. 281, 16521–16529 10.1074/jbc.M513827200 [DOI] [PubMed] [Google Scholar]
- 14. Moe S. M., and Chen N. X. (2001) The role of the synovium and cartilage in the pathogenesis of β2-microglobulin amyloidosis. Semin. Dial. 14, 127–130 10.1046/j.1525-139x.2001.00032.x [DOI] [PubMed] [Google Scholar]
- 15. Giorgetti S., Rossi A., Mangione P., Raimondi S., Marini S., Stoppini M., Corazza A., Viglino P., Esposito G., Cetta G., Merlini G., and Bellotti V. (2005) β2-Microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci. 14, 696–702 10.1110/ps.041194005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Wyatt A. R., Yerbury J. J., Dabbs R. A., and Wilson M. R. (2012) Roles of extracellular chaperones in amyloidosis. J. Mol. Biol. 421, 499–516 10.1016/j.jmb.2012.01.004 [DOI] [PubMed] [Google Scholar]
- 17. Myers S. L., Jones S., Jahn T. R., Morten I. J., Tennent G. A., Hewitt E. W., and Radford S. E. (2006) A systematic study of the effect of physiological factors on β2-microglobulin amyloid formation at neutral pH. Biochemistry 45, 2311–2321 10.1021/bi052434i [DOI] [PubMed] [Google Scholar]
- 18. Relini A., De Stefano S., Torrassa S., Cavalleri O., Rolandi R., Gliozzi A., Giorgetti S., Raimondi S., Marchese L., Verga L., Rossi A., Stoppini M., and Bellotti V. (2008) Heparin strongly enhances the formation of β2-microglobulin amyloid fibrils in the presence of type I collagen. J. Biol. Chem. 283, 4912–4920 10.1074/jbc.M702712200 [DOI] [PubMed] [Google Scholar]
- 19. Eakin C. M., and Miranker A. D. (2005) From chance to frequent encounters: origins of β2-microglobulin fibrillogenesis. Biochim. Biophys. Acta 1753, 92–99 10.1016/j.bbapap.2005.09.002 [DOI] [PubMed] [Google Scholar]
- 20. Platt G. W., and Radford S. E. (2009) Glimpses of the molecular mechanisms of β2-microglobulin fibril formation in vitro: aggregation on a complex energy landscape. FEBS Lett. 583, 2623–2629 10.1016/j.febslet.2009.05.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Esposito G., Michelutti R., Verdone G., Viglino P., Hernández H., Robinson C. V., Amoresano A., Dal Piaz F., Monti M., Pucci P., Mangione P., Stoppini M., Merlini G., Ferri G., and Bellotti V. (2000) Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci. 9, 831–845 10.1110/ps.9.5.831 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Eichner T., Kalverda A. P., Thompson G. S., Homans S. W., and Radford S. E. (2011) Conformational conversion during amyloid formation at atomic resolution. Mol. Cell 41, 161–172 10.1016/j.molcel.2010.11.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Bellotti V., Stoppini M., Mangione P., Sunde M., Robinson C., Asti L., Brancaccio D., and Ferri G. (1998) β2-Microglobulin can be refolded into a native state from ex vivo amyloid fibrils. Eur. J. Biochem. 258, 61–67 10.1046/j.1432-1327.1998.2580061.x [DOI] [PubMed] [Google Scholar]
- 24. Jahn T. R., Parker M. J., Homans S. W., and Radford S. E. (2006) Amyloid formation under physiological conditions proceeds via a native-like folding intermediate. Nat. Struct. Mol. Biol. 13, 195–201 10.1038/nsmb1058 [DOI] [PubMed] [Google Scholar]
- 25. Iadanza M. G., Silvers R., Boardman J., Smith H. I., Karamanos T. K., Debelouchina G. T., Su Y., Griffin R. G., Ranson N. A., and Radford S. E. (2018) The structure of a β2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. Nat. Commun. 9, 4517 10.1038/s41467-018-06761-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Karamanos T. K., Kalverda A. P., Thompson G. S., and Radford S. E. (2014) Visualization of transient protein-protein interactions that promote or inhibit amyloid assembly. Mol. Cell 55, 214–226 10.1016/j.molcel.2014.05.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Sarell C. J., Woods L. A., Su Y., Debelouchina G. T., Ashcroft A. E., Griffin R. G., Stockley P. G., and Radford S. E. (2013) Expanding the repertoire of amyloid polymorphs by co-polymerization of related protein precursors. J. Biol. Chem. 288, 7327–7337 10.1074/jbc.M112.447524 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Hasegawa K., Tsutsumi-Yasuhara S., Ookoshi T., Ohhashi Y., Kimura H., Takahashi N., Yoshida H., Miyazaki R., Goto Y., and Naiki H. (2008) Growth of β2-microglobulin-related amyloid fibrils by non-esterified fatty acids at a neutral pH. Biochem. J. 416, 307–315 10.1042/BJ20080543 [DOI] [PubMed] [Google Scholar]
- 29. Yamamoto S., Hasegawa K., Yamaguchi I., Tsutsumi S., Kardos J., Goto Y., Gejyo F., and Naiki H. (2004) Low concentrations of sodium dodecyl sulfate induce the extension of β2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 43, 11075–11082 10.1021/bi049262u [DOI] [PubMed] [Google Scholar]
- 30. Yamamoto S., Yamaguchi I., Hasegawa K., Tsutsumi S., Goto Y., Gejyo F., and Naiki H. (2004) Glycosaminoglycans enhance the trifluoroethanol-induced extension of β2-microglobulin-related amyloid fibrils at a neutral pH. J. Am. Soc. Nephrol 15, 126–133 10.1097/01.ASN.0000103228.81623.C7 [DOI] [PubMed] [Google Scholar]
- 31. Morgan C. J., Gelfand M., Atreya C., and Miranker A. D. (2001) Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. J. Mol. Biol. 309, 339–345 10.1006/jmbi.2001.4661 [DOI] [PubMed] [Google Scholar]
- 32. Calabrese M. F., Eakin C. M., Wang J. M., and Miranker A. D. (2008) A regulatable switch mediates self-association in an immunoglobulin fold. Nat. Struct. Mol. Biol. 15, 965–971 10.1038/nsmb.1483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Jahn T. R., Tennent G. A., and Radford S. E. (2008) A common β-sheet architecture underlies in vitro and in vivo β2-microglobulin amyloid fibrils. J. Biol. Chem. 283, 17279–17286 10.1074/jbc.M710351200 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. San Antonio J. D., Lander A. D., Karnovsky M. J., and Slayter H. S. (1994) Mapping the heparin-binding sites on type I collagen monomers and fibrils. J. Cell Biol. 125, 1179–1188 10.1083/jcb.125.5.1179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Ramachandran G. N., and Kartha G. (1955) Structure of collagen. Nature 176, 593–595 10.1038/176593a0 [DOI] [PubMed] [Google Scholar]
- 36. Brodsky B., Li M. H., Long C. G., Apigo J., and Baum J. (1992) NMR and CD studies of triple-helical peptides. Biopolymers 32, 447–451 10.1002/bip.360320423 [DOI] [PubMed] [Google Scholar]
- 37. Bella J., Liu J., Kramer R., Brodsky B., and Berman H. M. (2006) Conformational effects of Gly-X-Gly interruptions in the collagen triple helix. J. Mol. Biol. 362, 298–311 10.1016/j.jmb.2006.07.014 [DOI] [PubMed] [Google Scholar]
- 38. Long C. G., Braswell E., Zhu D., Apigo J., Baum J., and Brodsky B. (1993) Characterization of collagen-like peptides containing interruptions in the repeating Gly-X-Y sequence. Biochemistry 32, 11688–11695 10.1021/bi00094a027 [DOI] [PubMed] [Google Scholar]
- 39. Esposito G., Garvey M., Alverdi V., Pettirossi F., Corazza A., Fogolari F., Polano M., Mangione P. P., Giorgetti S., Stoppini M., Rekas A., Bellotti V., Heck A. J., and Carver J. A. (2013) Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers. J. Biol. Chem. 288, 17844–17858 10.1074/jbc.M112.448639 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Sultan A., Raman B., Rao Ch. M., and Tangirala R. (2013) The extracellular chaperone haptoglobin prevents serum fatty acid-promoted amyloid fibril formation of β2-microglobulin, resistance to lysosomal degradation, and cytotoxicity. J. Biol. Chem. 288, 32326–32342 10.1074/jbc.M113.498337 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Arosio P., Michaels T. C., Linse S., Månsson C., Emanuelsson C., Presto J., Johansson J., Vendruscolo M., Dobson C. M., and Knowles T. P. (2016) Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 10.1038/ncomms10948 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Stewart K. L., and Radford S. E. (2017) Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation. Biophys. Rev. 9, 405–419 10.1007/s12551-017-0271-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Goodchild S. C., Sheynis T., Thompson R., Tipping K. W., Xue W. F., Ranson N. A., Beales P. A., Hewitt E. W., and Radford S. E. (2014) β2-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH. PLoS One 9, e104492 10.1371/journal.pone.0104492 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Yamamoto K., Yagi H., Ozawa D., Sasahara K., Naiki H., and Goto Y. (2008) Thiol compounds inhibit the formation of amyloid fibrils by β2-microglobulin at neutral pH. J. Mol. Biol. 376, 258–268 10.1016/j.jmb.2007.12.002 [DOI] [PubMed] [Google Scholar]
- 45. Stewart K. L., Hughes E., Yates E. A., Akien G. R., Huang T. Y., Lima M. A., Rudd T. R., Guerrini M., Hung S. C., Radford S. E., and Middleton D. A. (2016) Atomic details of the interactions of glycosaminoglycans with amyloid-β fibrils. J. Am. Chem. Soc. 138, 8328–8331 10.1021/jacs.6b02816 [DOI] [PubMed] [Google Scholar]
- 46. Stewart K. L., Hughes E., Yates E. A., Middleton D. A., and Radford S. E. (2017) Molecular origins of the compatibility between glycosaminoglycans and Aβ40 amyloid fibrils. J. Mol. Biol. 429, 2449–2462 10.1016/j.jmb.2017.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Iannuzzi C., Borriello M., Carafa V., Altucci L., Vitiello M., Balestrieri M. L., Ricci G., Irace G., and Sirangelo I. (2016) d-Ribose-glycation of insulin prevents amyloid aggregation and produces cytotoxic adducts. Biochim. Biophys. Acta 1862, 93–104 10.1016/j.bbadis.2015.10.021 [DOI] [PubMed] [Google Scholar]
- 48. Habchi J., Chia S., Limbocker R., Mannini B., Ahn M., Perni M., Hansson O., Arosio P., Kumita J. R., Challa P. K., Cohen S. I., Linse S., Dobson C. M., Knowles T. P., and Vendruscolo M. (2017) Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 114, E200–E208 10.1073/pnas.1615613114 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Vranken W. F., Boucher W., Stevens T. J., Fogh R. H., Pajon A., Llinas M., Ulrich E. L., Markley J. L., Ionides J., and Laue E. D. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 10.1002/prot.20449 [DOI] [PubMed] [Google Scholar]
- 50. Quittot N., Sebastiao M., and Bourgault S. (2017) Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance. Biochem. Cell Biol. 95, 329–337 10.1139/bcb-2016-0236 [DOI] [PubMed] [Google Scholar]
- 51. Dobson J., Kumar A., Willis L. F., Tuma R., Higazi D. R., Turner R., Lowe D. C., Ashcroft A. E., Radford S. E., Kapur N., and Brockwell D. J. (2017) Inducing protein aggregation by extensional flow. Proc. Natl. Acad. Sci. U.S.A. 114, 4673–4678 10.1073/pnas.1702724114 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Mangione P. P., Esposito G., Relini A., Raimondi S., Porcari R., Giorgetti S., Corazza A., Fogolari F., Penco A., Goto Y., Lee Y. H., Yagi H., Cecconi C., Naqvi M. M., Gillmore J. D., et al. (2013) Structure and folding dynamics, and amyloidogenesis of D76N β2-microglobulin: role of shear flow, hydrophobic surfaces and α-crystallin. J. Biol. Chem. 288, 30917–30930 10.1074/jbc.M113.498857 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Debelouchina G. T., Platt G. W., Bayro M. J., Radford S. E., and Griffin R. G. (2010) Magic angle spinning NMR analysis of β2-microglobulin amyloid fibrils in two distinct morphologies. J. Am. Chem. Soc. 132, 10414–10423 10.1021/ja102775u [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Delaglio F., Grzesiek S., Vuister G. W., Zhu G., Pfeifer J., and Bax A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.